Next Article in Journal
Silver(I) Complexes with Clinically Used Azoles: Synthesis, Structural Characterization and Antimicrobial Evaluation
Previous Article in Journal
2-Styrylchromones Modulate Prostaglandins Production through the Inhibition of COX-2
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medical Sciences Forum
Volume 14
Issue 1
10.3390/ECMC2022-13494
msf-logo
Submit to this Journal
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Methoxyphenyl Imidazolines as Potential Activators of p53 †

by
Daniil R. Bazanov
1,*,
Nikolay V. Pervushin
2,
Natalia A. Lozinskaya
1 and
Gelina S. Kopeina
2
1
Department of Chemistry, M. V. Lomonosov Moscow State University, 119992 Moscow, Russia
2
Department of Medicine, M. V. Lomonosov Moscow State University, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
†
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
Med. Sci. Forum 2022, 14(1), 100; https://doi.org/10.3390/ECMC2022-13494
Published: 7 November 2022
(This article belongs to the Proceedings of The 8th International Electronic Conference on Medicinal Chemistry)
Versions Notes

Abstract

:
The use of p53-MDM2/X inhibitors is a prospective strategy in anti-cancer therapy for tumors with wild type p53 protein. In our study, new low-molecular-weight inhibitors of the p53-mdm2 interaction have been proposed. The two-step synthesis of the imidazoline core with subsequent modifications for the nitrogen atom was carried out. New molecules caused the accumulation of p53 protein levels more than seven times than in comparison with the control. The accumulation of proapoptotic proteins such as p21 and PUMA has also been investigated, and the mechanism of cell death has been shown.
Keywords:
p53; nutlin; mdm2; mdmx; imidazoline

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13494/s1.

Author Contributions

Investigation D.R.B., N.V.P.; Conceptualization N.A.L., G.S.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Russian Science Foundation, grant number 22-23-20141.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bazanov, D.R.; Pervushin, N.V.; Lozinskaya, N.A.; Kopeina, G.S. Methoxyphenyl Imidazolines as Potential Activators of p53. Med. Sci. Forum 2022, 14, 100. https://doi.org/10.3390/ECMC2022-13494

AMA Style

Bazanov DR, Pervushin NV, Lozinskaya NA, Kopeina GS. Methoxyphenyl Imidazolines as Potential Activators of p53. Medical Sciences Forum. 2022; 14(1):100. https://doi.org/10.3390/ECMC2022-13494

Chicago/Turabian Style

Bazanov, Daniil R., Nikolay V. Pervushin, Natalia A. Lozinskaya, and Gelina S. Kopeina. 2022. "Methoxyphenyl Imidazolines as Potential Activators of p53" Medical Sciences Forum 14, no. 1: 100. https://doi.org/10.3390/ECMC2022-13494

Article Metrics

Back to TopTop